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Abstract
Purpose: No consensus exists regarding the most effective form of pancreaticojejunostomy (PJ) following pancreaticoduodenectomy (PD).
Methods: Data were gathered through the American College of Surgeons-National Surgical Quality Improvement Program, Pancreatectomy Demonstration Project. A total of 1781 patients underwent a PD at 43 institutions. After appropriate exclusions, 890 patients were analyzed. Patients were divided into duct-to-mucosa
(n = 734, 82%) and invagination (n = 156, 18%) groups and were compared by unadjusted analysis. Type of PJ
was included in eight separate morbidity and mortality multivariable analyses.
Results: Invagination patients had higher serum albumin ( p < 0.01) and lower body mass index ( p < 0.01), were
less likely to have a preoperative biliary stent ( p < 0.01), and were more likely to have a soft gland ( p < 0.01). PJ
anastomosis type was not associated with morbidity but was associated with mortality (duct-to-mucosa vs. invagination, odds ratio = 0.22, p < 0.01). Among patients who developed a clinically relevant pancreatic ﬁstula,
none of the 119 duct-to-mucosa, compared with 5 of 21 invagination, patients died ( p < 0.01).
Conclusion: Patients who undergo a PJ by duct-to-mucosa or invagination differ with respect to preoperative
and intraoperative variables. When an invagination PJ leaks, there may be a greater inﬂuence on mortality than
when a duct-to-mucosa PJ leaks.
Keywords: pancreatic adenocarcinoma, pancreatic ﬁstula, pancreaticoduodenectomy, pancreaticojejunostomy

for pancreatic reconstruction, the PJ is generally considered the ‘‘Achilles’ heel’’ of PD, due not only to the relatively high incidence of leakage but also the signiﬁcance
in terms of patient recovery.6 Research studies and reviews generally place the incidence of clinically signiﬁcant
POPF to be between 10% and 30%. Although not commonly seen, very severe uncontrolled POPF can even
lead to postoperative mortality.7,8 Studies have reported
mortality rates related to severe POPF ranging from
20% to 40%.4,9,10 Given this high risk, an emphasis on decreasing complications associated with the PJ anastomosis
is needed to maximize the curative beneﬁt of PD.

Introduction
Patients with pancreatic ductal adenocarcinoma (PDA)
have an 8% overall 5-year survival rate, with the most effective current therapy being primary tumor resection.1,2
Pancreaticoduodenectomy (PD) is the most common
surgical procedure performed for resection of PDA; however, this complex operation is associated with a high
perioperative complication rate. The most common signiﬁcant complication associated with PD is a postoperative pancreatic ﬁstula (POPF), which is a leakage of
amylase-rich ﬂuid from the site of the pancreaticojejunostomy (PJ).1,3–5 Among the three anastomoses performed
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Considerable efforts have been made to reduce the incidence of PF in the past 30 years. Fistula mitigation strategies include alternative anastomosis techniques, the use
and management of intraperitoneal drains, ﬁbrin glue,
and pharmacological agents, among others. None of
these methods has proven to be deﬁnitively effective.11–14 The two standard techniques to restore gastrointestinal continuity for the pancreas are the invagination
PJ (IPJ), also known as the ‘‘dunking technique,’’ and the
duct-to-mucosa pancreaticojejunostomy (DmPJ). In the
IPJ method, the surgeon opens a portion of the jejunum
sufﬁcient to ‘‘dunk’’ the pancreatic stump into the side of
the jejunum. This technique requires a larger jejunotomy
than the competing DmPJ method, where the surgeon
makes a small jejunotomy that corresponds only to the
size of the pancreatic duct. Sutures are placed directly between the pancreatic duct and the jejunal mucosa, allowing for close adhesion of the two layers.15–17 A number of
studies have compared the effectiveness of DmPJ and
IPJ. One retrospective, single-institution study revealed
a 3.2% rate of POPF in the DmPJ group and a rate of
17.5% in its IPJ group without signiﬁcant mortality
differences.18 One dual-institution controlled trial,
however, found an odds ratio (OR) of 2.4 for POPF incidence between DmPJ and IPJ, again without significant mortality differences.6 Still, other studies have
reported minimal to no difference in risk of ﬁstula formation or mortality.15,19,20 One of the limitations to
prior studies is that they were restricted to single or
small multi-institutional trials. Given the contradicting
conclusions of previous research, more investigation into
the effectiveness of these techniques for pancreatic anastomotic reconstruction is warranted.
In this study, we aim to retrospectively compare
morbidity and mortality between invagination and
duct-to-mucosa PJ from the multi-institutional American College of Surgeons-National Surgical Quality
Improvement Program (ACS-NSQIP) Pancreatectomy
Demonstration Project (PDP).
Methods
Pancreatectomy demonstration project
A multicenter, retrospective cohort study was performed
to evaluate morbidity and mortality between invagination and duct-to-mucosa pancreaticojejunostomy. This
retrospective analysis was considered exempt by the
Institutional Review Board of Thomas Jefferson University. Data were gathered through the ACS-NSQIP,
PDP. This initiative gathered pancreatectomy-speciﬁc
data from 43 participating hospitals (see the Acknowl-
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edgments section). Data were collected from November 1, 2011, through December 31, 2012. Data
collection was standardized by utilizing trained surgical clinical reviewers (SCRs) within ACS-NSQIP. The
SCRs have ongoing data audits and follow precise definitions for data characteristics. Procedures are
recorded into the ACS-NSQIP database using Current
Procedural Technology codes. These processes have
been proven to ensure effective, high-volume data
entry into the NSQIP database.21 Further details regarding the PDP have previously been published.22–26
Study patients
During the study period, 2805 patients underwent a
pancreatic resection at the 43 participating institutions.
Patients who underwent total pancreatectomy, distal
pancreatectomy, enucleation, and minimally invasive
PD were excluded. Patients who lacked data on gland
texture and duct size also were excluded, given the signiﬁcance of these two factors in POPF formation.27,28
As a result, 890 patients were available for analysis.
Data on patient demographics and comorbidities, preoperative laboratory values, intraoperative characteristics,
and postoperative outcomes were collected. Deﬁnitions
and instructions for data collection of these variables
can be found in the ACS-NSQIP Data Users Guide.29
Patients were divided into DmPJ and IPJ groups and
were compared by unadjusted univariate analyses.
Type of PJ was then included in eight separate morbidity
and mortality multivariable analyses.
Outcome measures
All outcomes recorded in the ACS-NSQIP were
assessed 30 days postoperatively, except mortality,
which could be indicated at any time postdischarge.
The primary outcomes of this study were perioperative
overall morbidity, serious morbidity as previously deﬁned,22–26 mortality, and POPF-associated mortality.
Aside from the variables collected by general participation in ACS-NSQIP, the 43 institutions participating in
the PDP recorded 24 additional pancreatectomyspeciﬁc variables.22–25 The PDP-speciﬁc variables included in this study were preoperative biliary stenting,
chemotherapy and radiation 90 days before PD, pancreatic texture, pancreatic duct size, vascular resection,
pancreatic reconstruction method (DmPJ or IPJ), intraperitoneal drain placement, drain removal, drain
amylase, delayed gastric emptying, POPF, percutaneous drainage, and presence of malignant histology.
ACS-NSQIP PDP deﬁnitions have been published in
the ACS-NSQIP Procedure Targeted Pancreatectomy
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Variables and Deﬁnitions.29 POPF was deﬁned by two
scenarios: (1) persistent drain output of amylase-rich
ﬂuid of three times the concentration of serum amylase
on or after POD 3 in addition to one of the following
(drain continuation for longer than 7 days, percutaneous
drainage was performed, or reoperation was required) or
(2) the clinical diagnosis of POPF by the attending surgeon as well as drain continuation for longer than 7 days,
presence of spontaneous wound drainage, percutaneous
drainage was performed, or reoperation was required.
Data analysis
Continuous study variables were summarized between
reconstruction groups by their medians and the ﬁrst
and third quartiles and tested for signiﬁcant difference
by Wilcoxon rank sum tests. Categorical study variables were summarized between reconstruction groups
by their frequencies and percentages and tested for signiﬁcant dependencies by Fisher’s exact tests. Logistic
regression models were used to evaluate the likelihood
of binary endpoints (overall mortality during followup, overall morbidity, pancreatic ﬁstula, and reoperation) associated with reconstruction (i.e., DmPJ vs.
IPJ). Covariates included age (categorized in 10-year
groups), body mass index (BMI: kg/m2 categorized
using World Health Organization guidelines for underweight, normal weight, overweight, obese I, and obese
II), sex, preoperative biliary stent, albumin (below vs.
‡3.5 g/dL), texture (soft, intermediate, or hard), and
duct size (under 3, 3–6, and >6 mm). Due to the
small number of mortality events observed, we used a
stepwise selection procedure to identify a model with
3 (or fewer) parameters. The signiﬁcance level for all
tests was 0.05, and all analyses were conducted in
SAS version 9.4 (Cary, NC).
Results
Study population
During the 14-month study period, 1781 patients underwent PD at 43 participating institutions. After exclusions
as outlined above, 890 patients were available for analysis.
Of these patients, 735 (82%) underwent DmPJ and 156
(18%) underwent IPJ. Age and gender were similar between DmPJ and IPJ groups (Table 1). The DmPJ patients were found to have a signiﬁcantly lower median
serum albumin (3.8 vs. 4.1 g/dL, p < 0.01), higher median
serum bilirubin level (0.80 vs. 0.60 g/dL, p = 0.02), and
higher median BMI (26.2 vs. 24.6, p = 0.01). DmPJ patients also were more likely to have a preoperative biliary
stent (53% vs. 41%, p = 0.01) and were more likely to have
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Table 1. Patient Demographics and Preoperative Variables
for 890 Patients

a

Age (years)
Male
BMIa
Diabetes mellitus
Cigarette smoking
Biliary stent
Preoperative chemotherapy
Preoperative radiation
Albumin (g/dL)a
Bilirubin (g/dL)a
BUN (g/dL)a

Duct-to-mucosal

Invagination

n = 734 (82%)

n = 156 (18%)

p

65.8 [57.4, 73.1]
398 (54%)
26.2 [22.9, 30.4]
196 (27%)
163 (22%)
386 (53%)
66 (9%)
34 (5%)
3.8 [3.30, 4.20]
0.80 [0.50, 2.0]
13 [10, 18]

65.9 [59.6, 73.4]
81 (52%)
24.5 [22.3, 28.6]
30 (19%)
30 (19%)
64 (41%)
6 (4%)
2 (1%)
4.1 [3.7, 4.4]
0.60 [0.40, 1.80]
15 [11, 20]

0.50
0.66
0.01
0.10
0.45
0.01
0.04
0.07
0.01
0.02
0.02

a
Summarized by median with [ﬁrst, third quartiles].
BMI, body mass index; BUN, blood urea nitrogen.

undergone neoadjuvant chemotherapy (DmPJ: 9% vs.
4%, p = 0.04). Intraoperatively, DmPJ patients had different malignant histologies (84% vs. 79% cancer or intraductal papillary mucinous neoplasm (IPMN), 12% vs.
8% neuroendocrine tumor, p < 0.05), but were less likely
to have a soft gland (36% vs. 47%, p < 0.01; Table 2).
Outcomes
Overall morbidity and serious morbidity were similar between the two groups (Table 3; Fig. 1). Patients in each
group developed complications, including POPF, at similar rates. Both groups also underwent postoperative percutaneous drainage and reoperation at similar rates.
However, type of PJ did not inﬂuence any of these morbidity outcomes (Tables 3 and 4). On the contrary, overall mortality was higher in invagination patients (1% vs.
5%, p = 0.02, Fig. 2). In a logistic regression model adjusted for selected covariates (including sex and albumin
indicator as covariates), DmPJ was associated with about
a ﬁfth the odds of mortality compared with IPJ (OR =
0.22, 95% conﬁdence interval [0.08–0.64], p < 0.01;
Table 4). Among patients who developed POPF, none
Table 2. Intraoperative Variables
Duct-to-mucosal, n (%) Invagination, n (%)
Soft gland texture
Duct size <3 mm
Vascular resection
Antecholic DJ/GJ
Drain placement
Clean contaminated

261
234
90
413
577
609

(36)
(32)
(13)
(65)
(81)
(83)

Malignant histology
CA or IPMN
Neuroendocrine
Other

244 (84)
34 (12)
11 (4)

74
53
19
46
137
148

p

(47)
(34)
(13)
(39)
(92)
(95)

0.01
0.78
1.00
0.01
0.01
0.01

38 (79)
4 (8)
6 (13)

0.05

CA, cancer antigen; DJ/GJ, duodenojejunostomy/gastrojejunostomy;
IPMN, intraductal papillary mucinous neoplasm.
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Table 3. Perioperative Outcomes
Duct-to-mucosal, n (%) Invagination, n (%)
Overall morbidity
Serious morbidity
POPF
Any SSI
Organ space SSI
DGE
DVT
Percutaneous drain
Reoperation
Length of staya

372 (51)
323 (44)
120 (17)
160 (22)
67 (9)
123 (17)
11 (2)
63 (9)
19 (3)
8 [7, 13]

68 (44)
58 (37)
21 (14)
29 (19)
18 (12)
24 (16)
5 (3)
21 (15)
6 (4)
8 [6, 11]

p
0.11
0.13
0.54
0.45
0.37
0.90
0.18
0.07
0.43
0.13

a
Summarized by median with [ﬁrst, third quartiles].
DGE, delayed gastric emptying; DVT, deep vein thrombosis; POPF,
postoperative pancreatic ﬁstula; SSI, surgical-site infection.

of the 119 DmPJ patients, compared with 5 of 21 invagination patients, suffered postoperative mortality (0% vs.
24% p < 0.01; Fig. 2).
Discussion
POPF is among the most serious complications associated with PD and has broad implications for patient outcomes and recovery from this complex operation. In this
multi-institution, retrospective cohort study, we evaluated the inﬂuence of the type of PJ on morbidity and
mortality. Our analysis suggests an increased risk of
overall and POPF-related mortality associated with IPJ
compared with DmPJ. These data were adjusted for
age, gender, BMI, preoperative albumin levels, and
placement of biliary stents, and gland texture and
duct diameter via multivariate analysis. The absence of

POPF-associated mortality in the DmPJ group compared with the 24% POPF-associated mortality in the
IPJ group ( p < 0.01) suggests that DmPJ may be the
safer technique of pancreatic reconstruction.
Surgeon training, judgment, and comfort level are
important variables that go into the consideration of
the type of PJ anastomosis to perform.30–32 Some authorities argue that no single method of PJ can be applied ubiquitously to all patients and that tailoring
the method of PJ construction to the patient and the
type of gland is the best way to decrease POPF.10,28
Small duct diameter and soft pancreatic texture are
well documented to increase the risk of complication
during pancreatic reconstruction.6,7,20,30,33,34
The pathological cause of POPF in instances of small
duct diameter and soft pancreatic texture may be fundamentally different depending on the method of reconstruction. Small duct diameter is more likely to
lead to improper placement of sutures in the DmPJ
anastomosis leading to the potential for distraction of
ﬂow across the anastomosis resulting in leakage of pancreatic juice. Whereas in the IPJ anastomosis, the extensive suture placement and necessary compression
required to perform the invagination technique in patients with soft pancreatic tissue can cause ischemia,
laceration, and dehiscence resulting in a POPF.28,30,35
The IPJ also juxtaposes the open end of the pancreatic
remnant to the intestinal lumen. This architecture increases the likelihood for enzymatic erosion of the

FIG. 1. Postoperative outcomes in patients receiving DmPJ vs. IPJ reconstruction. DmPJ, duct-to-mucosa
pancreaticojejunostomy; IPJ, invagination pancreaticojejunostomy.
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Table 4. Logistic Regression Modeling
DmPJ vs. IPJ
Outcome variable

OR

95% CI

p

Overall mortality
Overall morbidity
Pancreatic fistula
Reoperation

0.22
1.22
1.35
0.66

(0.08–0.64)
(0.84–1.76)
(0.78–2.34)
(0.26–1.68)

0.01
0.30
0.28
0.38

Each row represents an indicator outcome regressed on a proceduretype indicator (DmPJ = 1, IPJ = 0) and covariates.
CI, conﬁdence interval; DmPJ, duct-to-mucosa pancreaticojejunostomy; IPJ, invagination pancreaticojejunostomy; OR, odds ratio.

pancreatic tissue, potentially causing necrosis, stenosis,
and subsequently POPF.29,34 Given the larger opening
in the jejunum associated with an IPJ anastomosis, in
the event of leakage, bile intermixed with pancreatic
juice may lead to further damage of surrounding tissues.
This situation may be more likely to result in an organ
space infection, sepsis, septic shock, and/or hemorrhage
from the gastroduodenal artery stump or other visceral
vasculatures.
Studies comparing DmPJ with IPJ after PD have focused primarily on POPF incidence as opposed to ﬁstularelated mortality. In the study by El Nakeeb et al.,28 107
patients were randomized into either end-to-side IPJ
or DmPJ groups after pancreatic resection. Patients
were followed for 1 year postoperatively, and subsequent
analysis revealed no signiﬁcant difference in POPF between DmPJ and IPJ.28 Three mortalities were reported
in the DmPJ group and four in the IPJ group, with only

some attributable to POPF. No subgroup analysis was
carried out on the causes of mortality.29
In the largest controlled trial of its type, Berger et al.6
randomized 197 patients from two institutions into
end-to-side IPJ and DmPJ groups. Analysis revealed a
24% POPF rate in the DmPJ group with a 12% POPF
in the IPJ group, and this difference was statistically
signiﬁcant. To our knowledge, this study is the only
one to have demonstrated a higher POPF rate with
DmPJ. Mortality was low in this study and comparable
between reconstruction methods—2% for DmPJ and
0% for IPJ.6 Both mortalities in the DmPJ group were
directly attributable to POPF. In addition, the study
also reported signiﬁcant differences in POPF rates between institutions as well as individual surgeons.
Based on the lack of a consensus in the literature of the
superior reconstruction method, we hypothesized that a
larger data set, including a diversity of surgeons and institutions, may reveal additional information regarding
POPF incidence, overall mortality, and POPF-associated
mortality between DmPJ and IPJ. Previous controlled trials were designed to detect POPF incidence differences
between techniques as a primary outcome. Consequently,
the largest trial had <100 patients in each group which,
given the already low mortality rates at high-volume centers, limited the assessment of mortality between techniques. Our retrospective analysis is the only study to
have demonstrated a signiﬁcantly increased mortality
risk in POPF patients undergoing the IPJ technique.

FIG. 2. Overall postoperative mortality (among all patients) and mortality following postoperative pancreatic
ﬁstula in patients receiving DmPJ vs. IPJ reconstruction.
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Several limitations are inherent to this retrospective
cohort study. First, data were retrieved from many surgeons at many institutions, and studies have reported a
wide variation in outcomes based on surgeon skill, experience, volume, and comfort level.6,26 However, potential skew in the data was balanced given that the
ACS-NSQIP PDP has input from 43 institutions. Second, this nonrandomized retrospective study is subject
to selection bias. Whether a particular method of pancreatic reconstruction was selected based on the characteristics of the pancreatic remnant intraoperatively
is unknown. For example, surgeons may have reserved
one method of reconstruction for patients deemed to
be at greater risk of POPF or other complications.
The differences in preoperative and intraoperative
characteristics may suggest this bias. However, the statistical methodology used in this study controlled for
many risk factors, which, in general, would have led
to more POPFs in the DmPJ group. The differences between the groups, including the factors of BMI, preoperative biliary stenting, and albumin, would tend to
favor the invagination group as it pertains to postoperative complications.
Third, despite multivariate analysis and exclusion
of patients without complete data, outcomes measured could have been inﬂuenced by confounding
factors not recorded in the database. For example,
surgeon experience and hospital volume data were
not available. Fourth, some parameters measured,
such as gland texture, are very difﬁcult to standardize
and left to the judgment of the surgeons even with
speciﬁc ACS-NSQIP deﬁnitions. Fifth, with respect
to mortality, relatively small numbers are available
from which to draw conclusions, and a limitation
of the NSQIP database is that we do not have information on the actual cause of death. We can report
the association of death with type of anastomosis
performed but cannot deﬁnitively prove a causal
link. The NSQIP database is also limited by the lack
of information on pancreatic stents, octreotide, and
ﬁbrin glue use. Finally, the DmPJ group was signiﬁcantly larger (n = 734) compared with the IPJ group
(n = 156), which suggests a national bias and perhaps
more experience with this technique.
As for the generalizability of this research, an advantage is that it is the largest study evaluating the two most
common methods of pancreatic reconstruction after PD.
In the PDP, only 4% of patients had a PG. In addition, a
recent multi-institution, prospective randomized trial
from Germany suggests that PG is associated with in-
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creased postoperative bleeding compared with PJ.36
The diversity of the data obtained through the ACSNSQIP PDP may make this study applicable to hepatopancreatobiliary surgeons both in training and in
practice. Given the signiﬁcant mortality differences between DmPJ and IPJ, future investigation into the safest
method for reconstruction should be powered to address
difference in mortality as well as POPF.
Conclusion
This analysis suggests that patients undergoing a PJ by
DmPJ or IPJ differ with respect to several preoperative
and intraoperative variables. Nevertheless, pancreatic
ﬁstula rates did not differ signiﬁcantly, but mortality was signiﬁcantly greater with an IPJ, particularly
among those experiencing pancreatic ﬁstula. Thus,
when an invaginated PJ leaks, there may be a signiﬁcant impact on mortality.
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